文献速递临床试验与 GCP基础与转化研究

高蛋白饮食联合β-隐黄质补充对非酒精性脂肪肝代谢风险因素、氧化及炎症生物标志物的影响:随机对照临床试验研究方案

Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2018-11-16

BACKGROUND: Excessive hepatic fat is associated with increased metabolic risk factors, production of inflammatory factors, and oxidative stress. High protein intake might trigger an increased hepatic lipid oxidation through an increase in hepatic energy expenditure.…

要点

  • 高蛋白饮食可能通过增加肝脏能量消耗促进肝脏脂质氧化。
  • β-隐黄质对非酒精性脂肪肝的防治作用尚需随机对照试验验证。
  • 试验为期12周,β-隐黄质日补充剂量为6 mg,联合高蛋白饮食。

核心结论

  • 该试验旨在探究β-隐黄质补充联合高蛋白饮食对非酒精性脂肪肝患者代谢及炎症指标的影响,并确定无需能量限制的最佳宏量营养素比例。

关键数值与推荐

  • β-隐黄质日补充剂量为6 mg;干预持续12周;纳入标准为年龄18-60岁、BMI 25-40 kg/m2。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Excessive hepatic fat is associated with increased metabolic risk factors, production of inflammatory factors, and oxidative stress. High protein intake might trigger an increased hepatic lipid oxidation through an increase in hepatic energy expenditure. Furthermore, the majority of randomized controlled trials (RCT) in humans have failed to show whether carotenoids can be used to prevent and treat non-alcoholic fatty liver disease (NAFLD). However, it is notable and contradictory that NAFLD is rapidly escalating in Iran and other countries with lower intakes of fruit and vegetables (as sources of β-cryptoxanthin [β-CX] and carbohydrates) and higher intake of carbohydrates (as an agent of NAFLD); and the effects of β-CX and a high protein diet (HPD) on NAFLD need to be investigated further. METHODS/DESIGN: This study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for 12 weeks to receive daily β-CX 6 mg supplementation combined with a HPD on levels of metabolic factors, β-CX, glycemic and lipid profiles, inflammatory factors, adipocytokines, and body composition. Ninety-two eligible patients, aged 18-60 years, of both genders, who are obese and overweight (body mass index [BMI] 25-40 kg/m2) will be randomly assigned to four groups as follow: HPD + placebo; normal protein diet + β-CX (NPD + β-CX); HPD + β-CX; and NPD + placebo (control group). Two populations will be analyzed in this work. The intention-to-treat (ITT) population includes all patients who will be randomized, while the per-protocol (PP) population includes all individuals who complete the 12- week intervention (i.e. study completers). DISCUSSION: Our findings from this trial will contribute to the knowledge of the relationship between β-CX supplementation and a HPD on NAFLD patients and determination of optimal macronutrient ratios without energy restriction. TRIAL REGISTRATION: Iran clinical trials registry, IRCT2017060210181N10 . Registered on 20 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Haidari F, Hojhabrimanesh A, Helli B, et al. Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial. Trials. 2018. PMID: 30445988. doi:10.1186/s13063-018-3014-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。